Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All zinc studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchZincZinc (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?

Derwand et al., Medical Hypotheses, doi:10.1016/j.mehy.2020.109815 (date from preprint)
Apr 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Zinc for COVID-19
2nd treatment shown to reduce risk in July 2020
 
*, now known with p = 0.0000027 from 43 studies, recognized in 10 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Hypothesis that HCQ/CQ + zinc will be more effective than HCQ/CQ alone for COVID-19.
Reviews covering zinc for COVID-19 include Arora, Briassoulis, Derwand, DiGuilio, Foshati, Joachimiak, Schloss, Sethuram.
Study covers zinc and HCQ.
Derwand et al., 6 Apr 2020, peer-reviewed, 2 authors. Contact: martin.scholz@leukocare.com.
This PaperZincAll
Does zinc supplementation enhance the clinical efficacy of chloroquine/ hydroxychloroquine to win today's battle against COVID-19?
R Derwand, M Scholz
Currently, drug repurposing is an alternative to novel drug development for the treatment of COVID-19 patients. The antimalarial drug chloroquine (CQ) and its metabolite hydroxychloroquine (HCQ) are currently being tested in several clinical studies as potential candidates to limit SARS-CoV-2-mediated morbidity and mortality. CQ and HCQ (CQ/HCQ) inhibit pH-dependent steps of SARS-CoV-2 replication by increasing pH in intracellular vesicles and interfere with virus particle delivery into host cells. Besides direct antiviral effects, CQ/HCQ specifically target extracellular zinc to intracellular lysosomes where it interferes with RNA-dependent RNA polymerase activity and coronavirus replication. As zinc deficiency frequently occurs in elderly patients and in those with cardiovascular disease, chronic pulmonary disease, or diabetes, we hypothesize that CQ/HCQ plus zinc supplementation may be more effective in reducing COVID-19 morbidity and mortality than CQ or HCQ in monotherapy. Therefore, CQ/HCQ in combination with zinc should be considered as additional study arm for COVID-19 clinical trials.
Conflict of interest The author Roland Derwand is/was at the time of writing an employee of Alexion Pharma Germany GmbH. The author Martin Scholz is/was at the time of writing External Senior Advisor for the company LEUKOCARE in Munich, Germany. The authors confirm that this article content has no conflict of interest.
References
Anderson, Roussel, Zouari, Mahjoub, Matheau et al., Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus, J Am Coll Nutr
Braun, Rosenfeldt, Pharmaco-nutrient interactions -a systematic review of zinc and antihypertensive therapy, Int J Clin Pract
Cao, Wang, Wen, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282
Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105932
Cui-Cui, Rw, Repurposing host-based therapeutics to control coronavirus and influenza virus, Drug Discovery Today
Ervin, Kennedy-Stephenson, Mineral intakes of elderly adult supplement and non-supplement users in the third national health and nutrition examination survey, J Nutr
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Kaushik, Subramani, Anang, Zinc salts block hepatitis E virus replication by inhibiting the activity of viral RNA-dependent RNA polymerase, J Virol, doi:10.1128/JVI.00754-17
Kearney, Chloroquine as a potential treatment and prevention measure for the 2019 novel coronavirus: a review, Preprints, doi:10.20944/preprints202003.0275
Kupferschmidt, Cohen, WHO launches global megatrial of the four most promising coronavirus treatments, Science
Prasad, Beck, Bao, Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress, Am J Clin Nutr
Read, Obeid, Ahlenstiel, Ahlenstiel, The role of zinc in antiviral immunity, Adv Nutr, doi:10.1093/advances/nmz013
Rolain, Colson, Raoult, Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century, Int J Antimicrob Agents
Smith, Bushek, Prosser, COVID-19 drug therapy potential options
Velthuis, Van Den Worm, She, Sims, Zn 2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture, PLoS Pathog, doi:10.1371/journal.ppat.1001176
Xue, Moyer, Peng, Wu, Hannafon et al., Chloroquine is a zinc ionophore, PLoS One, doi:10.1371/journal.pone.0109180
Yang, Shen, Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19, Int J Biol Sci, doi:10.7150/ijbs.45498
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit